ADMA Biologics (NASDAQ:ADMA) Shares Up 5.9% After Analyst Upgrade

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) traded up 5.9% on Monday after HC Wainwright raised their price target on the stock from $10.00 to $18.00. HC Wainwright currently has a buy rating on the stock. ADMA Biologics traded as high as $17.02 and last traded at $16.90. 1,038,502 shares were traded during trading, a decline of 65% from the average session volume of 2,985,036 shares. The stock had previously closed at $15.96.

Other equities analysts have also recently issued research reports about the stock. Raymond James boosted their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research note on Friday, May 10th. Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Finally, Mizuho increased their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics presently has an average rating of “Buy” and a consensus target price of $15.50.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of large investors have recently added to or reduced their stakes in the company. Mesirow Institutional Investment Management Inc. purchased a new position in shares of ADMA Biologics in the 1st quarter worth about $17,221,000. Rice Hall James & Associates LLC bought a new position in ADMA Biologics during the first quarter valued at approximately $7,963,000. Castleark Management LLC bought a new position in ADMA Biologics during the first quarter valued at approximately $5,400,000. Hillsdale Investment Management Inc. grew its position in ADMA Biologics by 41,893.3% during the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after acquiring an additional 628,400 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after acquiring an additional 575,100 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 5.0 %

The stock has a market capitalization of $4.00 billion, a P/E ratio of -848.00 and a beta of 0.55. The stock’s fifty day moving average price is $11.90 and its two-hundred day moving average price is $8.47. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.02) earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.